Quantitative Assessment of Elagolix Enzyme-Transporter Interplay and Drug-Drug Interactions Using Physiologically Based Pharmacokinetic Modeling.

Manoj S Chiney Juki W Ng John P Gibbs Mohamad Shebley

Published in: Clinical pharmacokinetics (2021)

A PBPK model of elagolix was developed, verified, and applied to characterize the disposition interplay between CYP3A4 and OATP1B1, and to predict the DDI potential of elagolix as a perpetrator under dosing conditions that were not tested clinically. PBPK model-based predictions were used to support labeling language for DDI recommendations of elagolix.

Keyphrases

autism spectrum disorder
emergency department
risk assessment
adverse drug
climate change